133 related articles for article (PubMed ID: 32999489)
1. Targeting LSD1 and FOXA1 in prostate cancer.
Omarjee S; Carroll JS
Nat Genet; 2020 Oct; 52(10):1002-1003. PubMed ID: 32999489
[No Abstract] [Full Text] [Related]
2. Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer.
Gao S; Chen S; Han D; Wang Z; Li M; Han W; Besschetnova A; Liu M; Zhou F; Barrett D; Luong MP; Owiredu J; Liang Y; Ahmed M; Petricca J; Patalano S; Macoska JA; Corey E; Chen S; Balk SP; He HH; Cai C
Nat Genet; 2020 Oct; 52(10):1011-1017. PubMed ID: 32868907
[TBL] [Abstract][Full Text] [Related]
3. Pioneer of prostate cancer: past, present and the future of FOXA1.
Teng M; Zhou S; Cai C; Lupien M; He HH
Protein Cell; 2021 Jan; 12(1):29-38. PubMed ID: 32946061
[TBL] [Abstract][Full Text] [Related]
4. SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1.
Wang Z; Petricca J; Liu M; Zhang S; Chen S; Li M; Besschetnova A; Patalano S; Venkataramani K; Siegfried KR; Macoska JA; Han D; Gao S; Vedadi M; Arrowsmith CH; He HH; Cai C
Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2220472120. PubMed ID: 37549269
[TBL] [Abstract][Full Text] [Related]
5. Unveiling the Molecular Landscape of
Hwang KW; Yun JW; Kim HS
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958805
[TBL] [Abstract][Full Text] [Related]
6. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
Parolia A; Cieslik M; Chu SC; Xiao L; Ouchi T; Zhang Y; Wang X; Vats P; Cao X; Pitchiaya S; Su F; Wang R; Feng FY; Wu YM; Lonigro RJ; Robinson DR; Chinnaiyan AM
Nature; 2019 Jul; 571(7765):413-418. PubMed ID: 31243372
[TBL] [Abstract][Full Text] [Related]
7. A rare variant, which destroys a FoxA1 site at 8q24, is associated with prostate cancer risk.
Hazelett DJ; Coetzee SG; Coetzee GA
Cell Cycle; 2013 Jan; 12(2):379-80. PubMed ID: 23255135
[No Abstract] [Full Text] [Related]
8. Forkhead domain mutations in FOXA1 drive prostate cancer progression.
Gao S; Chen S; Han D; Barrett D; Han W; Ahmed M; Patalano S; Macoska JA; He HH; Cai C
Cell Res; 2019 Sep; 29(9):770-772. PubMed ID: 31324883
[No Abstract] [Full Text] [Related]
9. FOXA1 regulates alternative splicing in prostate cancer.
Del Giudice M; Foster JG; Peirone S; Rissone A; Caizzi L; Gaudino F; Parlato C; Anselmi F; Arkell R; Guarrera S; Oliviero S; Basso G; Rajan P; Cereda M
Cell Rep; 2022 Sep; 40(13):111404. PubMed ID: 36170835
[TBL] [Abstract][Full Text] [Related]
10. Altered chromatin recruitment by FOXA1 mutations promotes androgen independence and prostate cancer progression.
Xu B; Song B; Lu X; Kim J; Hu M; Zhao JC; Yu J
Cell Res; 2019 Sep; 29(9):773-775. PubMed ID: 31324884
[No Abstract] [Full Text] [Related]
11. FOXA1: a transcription factor with parallel functions in development and cancer.
Bernardo GM; Keri RA
Biosci Rep; 2012 Apr; 32(2):113-30. PubMed ID: 22115363
[TBL] [Abstract][Full Text] [Related]
12. Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity.
Cai C; He HH; Gao S; Chen S; Yu Z; Gao Y; Chen S; Chen MW; Zhang J; Ahmed M; Wang Y; Metzger E; Schüle R; Liu XS; Brown M; Balk SP
Cell Rep; 2014 Dec; 9(5):1618-1627. PubMed ID: 25482560
[TBL] [Abstract][Full Text] [Related]
13. LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation.
He Y; Zhao Y; Wang L; Bohrer LR; Pan Y; Wang L; Huang H
Oncogene; 2018 Jan; 37(4):534-543. PubMed ID: 28991226
[TBL] [Abstract][Full Text] [Related]
14. The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer.
Kashyap V; Ahmad S; Nilsson EM; Helczynski L; Kenna S; Persson JL; Gudas LJ; Mongan NP
Mol Oncol; 2013 Jun; 7(3):555-66. PubMed ID: 23384557
[TBL] [Abstract][Full Text] [Related]
15. LSD1 dual function in mediating epigenetic corruption of the vitamin D signaling in prostate cancer.
Battaglia S; Karasik E; Gillard B; Williams J; Winchester T; Moser MT; Smiraglia DJ; Foster BA
Clin Epigenetics; 2017; 9():82. PubMed ID: 28811844
[TBL] [Abstract][Full Text] [Related]
16. Genetic alterations and changes in expression of histone demethylases in prostate cancer.
Suikki HE; Kujala PM; Tammela TL; van Weerden WM; Vessella RL; Visakorpi T
Prostate; 2010 Jun; 70(8):889-98. PubMed ID: 20127736
[TBL] [Abstract][Full Text] [Related]
17. Genetic features of TP53 mutation and its downstream FOXA1 in prostate cancer.
Xu X; Xie L; Meng L; Geng S; Liu J; Cao X; Dong Z; Xing Z
Biosci Trends; 2022 Jul; 16(3):221-229. PubMed ID: 35768267
[TBL] [Abstract][Full Text] [Related]
18. LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression.
Liang Y; Ahmed M; Guo H; Soares F; Hua JT; Gao S; Lu C; Poon C; Han W; Langstein J; Ekram MB; Li B; Davicioni E; Takhar M; Erho N; Karnes RJ; Chadwick D; van der Kwast T; Boutros PC; Arrowsmith CH; Feng FY; Joshua AM; Zoubeidi A; Cai C; He HH
Cancer Res; 2017 Oct; 77(20):5479-5490. PubMed ID: 28916652
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.
Jin HJ; Zhao JC; Ogden I; Bergan RC; Yu J
Cancer Res; 2013 Jun; 73(12):3725-36. PubMed ID: 23539448
[TBL] [Abstract][Full Text] [Related]
20. FOXA1 promotes prostate cancer angiogenesis by inducing multiple pro-angiogenic factors expression.
Su Y; Zhang Y; Zhao J; Zhou W; Wang W; Han B; Wang X
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3225-3243. PubMed ID: 34258652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
